UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36510 LARIMAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of inco ...

Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label studyContinued alignment with FDA to consider the use of skin FXN to support BLA submission seeking accelerated approval following recent START pilot program meetingTopline open label study data to support BLA submission expected in Q2 2026Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of first patie ...

Core Insights - Larimar Therapeutics (LRMR) shares increased by 55% over the past month following significant regulatory updates regarding nomlabofusp, its leading pipeline asset [1] Regulatory Updates - The FDA granted breakthrough therapy designation (BTD) to nomlabofusp for treating Friedreich's ataxia (FA), a rare neurodegenerative disorder [2] - BTD is intended to expedite the development and review of therapies for severe diseases where preliminary evidence suggests substantial improvements over existing treatments [3] Clinical Data - Preliminary data from an ongoing open-label study indicated increases in skin FXN levels comparable to asymptomatic carriers of the FA gene mutation [4] - The study demonstrated consistent improvement across four key clinical outcomes after one year of treatment, including mFARS, FARS-ADL, 9-HPT, and MFIS [4] - These findings suggest that nomlabofusp may slow disease progression compared to the worsening typically seen in untreated FA patients [5] Future Plans - Larimar received positive feedback from the FDA regarding a potential regulatory filing for nomlabofusp, with skin FXN levels considered as a novel surrogate endpoint [6] - Top-line data from the ongoing study is expected in Q2 2026, with plans to submit a regulatory filing to the FDA in June 2026 if results are positive [7] - A confirmatory late-stage study is planned, with the first patient dosing anticipated in mid-2026 [10][12] Market Context - The recent stock rally reflects improved investor confidence in Larimar's pipeline, which relies solely on nomlabofusp for growth [8] - The limited treatment landscape for FA, with only one approved drug (Skyclarys by Biogen), enhances the opportunity for nomlabofusp [9] - Year-to-date, Larimar's shares have risen by 37%, contrasting with the industry's breakeven growth [9]

Core Insights - Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases [3] Group 1: Company Overview - Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia [3] - The company plans to utilize its intracellular delivery platform to design other fusion proteins targeting additional rare diseases characterized by deficiencies in intracellular bioactive compounds [3] Group 2: Upcoming Events - Larimar's management team will present at the Leerink Partners Global Healthcare Conference on March 10, 2026, at 8:40 AM ET [2] - The company will also participate in The Citizens Life Sciences Conference on March 11, 2026, at 4:00 PM ET [2] - Webcast links for both presentations are provided for investor access [2]

Core Viewpoint - Wedbush has raised the price target for Larimar Therapeutics (LRMR) to $12 from $11 while maintaining an Outperform rating on the shares, indicating positive sentiment towards the company's future performance [1]. Group 1: Financial Developments - Larimar Therapeutics completed an upsized $100 million offering after receiving Breakthrough Therapy designation for nomlabofusp in Friedreich's ataxia, which is a significant milestone for the company [1]. - Following the capital raise, Wedbush is increasing its Q4 spending forecast to align with year-end 2025 cash projections of $137 million [1]. Group 2: Regulatory Environment - Despite recent FDA decisions causing investor concern, Wedbush remains optimistic as Larimar continues to engage in active dialogue with the agency, suggesting a proactive approach to regulatory challenges [1].

BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its upsized underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $5.00 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $100 million, before deducting underwriting discounts and commissions ...

Core Viewpoint - Larimar Therapeutics, Inc. has initiated a public offering of $75 million in common stock and pre-funded warrants, with an additional option for underwriters to purchase up to $11.25 million more, aimed at supporting the development of its lead compound, nomlabofusp, and for general corporate purposes [1][2]. Group 1 - Larimar is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with its lead compound targeting Friedreich's ataxia [5]. - The proposed offering is subject to market conditions and may not be completed as planned [1]. - J.P. Morgan and Guggenheim Securities are acting as joint bookrunning managers for the offering [2]. Group 2 - The net proceeds from the offering will be used for research and development expenses, commercialization expenses, and working capital [2]. - The offering is being made under a shelf registration statement declared effective by the SEC on May 24, 2024 [3]. - A preliminary prospectus supplement will be filed with the SEC and will be available for free on their website [3].

Core Viewpoint - Larimar Therapeutics Inc (NASDAQ:LRMR) is experiencing significant stock price increases due to positive analyst ratings and strong investor confidence, with a notable year-over-year stock price rise of 106.15% [2][4]. Analyst Ratings - Citigroup's Samantha Semenkow maintained a Buy rating and increased the price target from $12 to $14, while Wedbush's Laura Chico reaffirmed an Outperform rating with an $11 target [1]. Stock Performance - Larimar's stock is currently trading at $6.17, reflecting a 67.21% increase at the time of publication and reaching a new 52-week high [6]. - The stock is significantly above its key moving averages, with a 72.5% lead over the 50-day SMA and a 62.6% lead over the 100-day SMA, indicating a strong upward trend [2]. Technical Indicators - The Relative Strength Index (RSI) is at 58.66, suggesting the stock is neither overbought nor oversold, while the MACD being above its signal line indicates continued bullish momentum [3]. Sector Performance - Despite a slight pullback in the broader Healthcare sector, which is down 0.11%, Larimar Therapeutics has surged over 72%, showcasing its strong performance relative to its peers [4]. Benzinga Edge Score - Larimar received a moderate momentum score of 54.24 on the Benzinga Edge scorecard, reflecting its recent performance trends and potential for continued growth driven by innovative treatments [5].

Core Insights - Larimar Therapeutics has received Breakthrough Therapy status from the FDA, aimed at expediting the development of drugs that may enhance outcomes for serious conditions [2] - The company plans to submit a Biologics License Application (BLA) in 2026 for its protein replacement therapy, Nomlabofusp, targeting frataxin deficiency in Friedreich's ataxia [3] - Larimar's stock has shown significant upward momentum, trading 13.6% above its 20-day simple moving average and 23.01% higher over the past 12 months [4] FDA Breakthrough Therapy Status - The Breakthrough Therapy designation is intended to accelerate the development of drugs that could improve treatment outcomes compared to existing therapies [2] - Larimar's strategy includes using skin frataxin levels as a potential surrogate endpoint in its BLA for accelerated approval [2] Stock Performance - Larimar's shares increased by 31.67% to $3.70, with key resistance at $4.00 and support at $3.50 [6] - The stock is currently positioned closer to its 52-week highs, indicating a favorable long-term trend [4] Technical Indicators - The Relative Strength Index (RSI) is at 33.78, indicating neutral territory, while the MACD shows a value of -0.1482, suggesting bearish pressure [5] - The combination of a neutral RSI and bearish MACD indicates mixed momentum for the stock [5]

Larimar Therapeutics, Inc. (LRMR) shares soared 34.34 percent to $3.77, up $0.96 on Tuesday, after the company announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to nomlabofusp for the treatment of Friedreich's ataxia. The stock is currently trading at $3.9200, compared with a previous close of $2.8100. It opened at $3.5900 and has traded between $3.5500 and $4.0000 during the session. Trading volume has surged to 43.95 million shares, far exceeding its average vo ...